» Articles » PMID: 19086915

Effectiveness of Inactivated Influenza Vaccines Varied Substantially with Antigenic Match from the 2004-2005 Season to the 2006-2007 Season

Overview
Journal J Infect Dis
Date 2008 Dec 18
PMID 19086915
Citations 154
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We estimated the effectiveness of inactivated influenza vaccines for the prevention of laboratory-confirmed, medically attended influenza during 3 seasons with variable antigenic match between vaccine and patient strains.

Methods: Patients were enrolled during or after a clinical encounter for acute respiratory illness. Influenza infection was confirmed by culture or reverse-transcriptase polymerase chain reaction. Case-control analyses were performed that used data from patients who were ill without influenza (hereafter, "test-negative control subjects") and data from asymptomatic control subjects from the population (hereafter, "traditional control subjects"). Vaccine effectiveness (VE) was estimated as [100 x (1-adjusted odds ratio)]. Influenza isolates were antigenically characterized.

Results: Influenza was detected in 167 (20%) of 818 patients in 2004-2005, in 51 (14%) of 356 in 2005-2006, and in 102 (11%) of 932 in 2006-2007. Analyses that used data from test-negative control subjects showed that VE was 10% (95% confidence interval [CI], -36% to 40%) in 2004-2005, 21% (95% CI, -52% to 59%) in 2005-2006, and 52% (95% CI, 22% to 70%) in 2006-2007. Using data from traditional control subjects, VE for those seasons was estimated to be 5% (95% CI, -52% to 40%), 11% (95% CI, -96% to 59%), and 37% (95% CI, -10% to 64%), respectively; confidence intervals included 0. The percentage of viruses that were antigenically matched to vaccine strains was 5% (3 of 62) in 2004-2005, 5% (2 of 42) in 2005-2006, and 91% (85 of 93) in 2006-2007.

Conclusions: Influenza VE varied substantially across 3 seasons and was highest when antigenic match was optimal. VE estimates that used data from test-negative control subjects were consistently higher than those that used data from traditional control subjects.

Citing Articles

Adjuvant-free, self-assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses.

Zhao Y, Guo S, Liu J, Wang Y, Wang B, Peng C Front Immunol. 2025; 16:1519866.

PMID: 39958330 PMC: 11827429. DOI: 10.3389/fimmu.2025.1519866.


Expert consensus on the benefits of neuraminidase in conventional influenza vaccines: a Delphi study.

Youhanna J, Puig-Barbera J, Miller M, Molrine D, Hadi M, Bapat S BMC Infect Dis. 2025; 25(1):53.

PMID: 39794704 PMC: 11724539. DOI: 10.1186/s12879-024-10277-4.


Developing Correlates of Protection for Vaccines Is Needed More than Ever-Influenza, COVID-19 and RSV Infection.

Vajo Z, Laszlofy C Viruses. 2024; 16(11).

PMID: 39599786 PMC: 11598905. DOI: 10.3390/v16111671.


Forecasting and analyzing influenza activity in Hebei Province, China, using a CNN-LSTM hybrid model.

Li G, Li Y, Han G, Jiang C, Geng M, Guo N BMC Public Health. 2024; 24(1):2171.

PMID: 39135162 PMC: 11318307. DOI: 10.1186/s12889-024-19590-8.


MetaFluAD: meta-learning for predicting antigenic distances among influenza viruses.

Jia Q, Xia Y, Dong F, Li W Brief Bioinform. 2024; 25(5).

PMID: 39129362 PMC: 11317534. DOI: 10.1093/bib/bbae395.